Supply of interferon beta-1B (rbe)(EXTAVIA) 0.25mg (8 million IU) powder for injection vial with diluent syringe by Novartis Pharmaceuticals Australia Pty Ltd

Overview

The Therapeutic Goods Act 1989 was enacted to regulate the quality, safety, efficacy and timely availability of therapeutic goods in Australia. The Act was introduced to address the need for a comprehensive legal framework governing the approval, advertising, supply, and monitoring of therapeutic goods, including medicines, medical devices, and blood and blood components. This legislation is enacted by the Parliament of Australia and is administered by the Therapeutic Goods Administration (TGA). The primary policy objective of the Act is to protect public health by ensuring that therapeutic goods available in Australia meet acceptable standards of quality, safety, and efficacy. The Act provides the TGA with the authority to regulate the import, export, manufacture, and supply of therapeutic goods, as well as to monitor their post-market performance. The Act also empowers the TGA to take enforcement action against non-compliance and to restrict or prohibit the supply of therapeutic goods that pose an unacceptable risk to public health. In this particular case, the delegate of the Secretary has given consent for the supply of a specific batch of interferon beta-1B (rbe)(EXTAVIA) 0.25 mg (8 million IU) powder for injection vial with diluent syringe by Novartis Pharmaceuticals Australia Pty Ltd, under certain conditions, to address a non-compliance issue with the product labelling.

Scope and Application

The Therapeutic Goods Act 1989, as outlined in Section 14 and 14A Notice dated March 4, 2013, applies to the pharmaceutical industry and specifically to Novartis Pharmaceuticals Australia Pty Ltd. The legislation allows for the supply of a particular therapeutic good, interferon beta-1B (rbe) (EXTAVIA) 0.25 mg (8 million IU) powder for injection vial with diluent syringe, under certain conditions. This specific consent pertains to one batch of a maximum of 2000 units and is contingent upon compliance with conditions set by the delegate of the Secretary of the Department of Health and Ageing. The Act's jurisdiction extends across Australia, and the consent given is subject to the stipulations outlined in the Therapeutic Goods Order (TGO) 69, which pertains to general labelling requirements for medicines. However, for this particular batch, the biological source of the active ingredient and relevant warning statements on the syringe labels are exempted from certain compliance requirements, provided the outer carton adheres to the approved Australian specifications.

Key Provisions

The Therapeutic Goods Act 1989 (the Act) provides mechanisms for the regulation of therapeutic goods in Australia. Sections 14 and 14A of the Act allow the delegate of the Secretary of the Department of Health and Ageing to give consent to certain activities that might otherwise not comply with the regulations. In this case, section 14(1) enables the delegate to consent to the supply of goods that do not fully comply with specified regulations, while section 14A(1) allows for such consent to be given on certain conditions. This consent is provided under section 15(1) of the Act, which stipulates that the consent is subject to specific conditions to ensure that the therapeutic goods are still safe and of acceptable quality. Under the terms of this consent, Novartis Pharmaceuticals Australia Pty Ltd, North Ryde, NSW, is permitted to supply interferon beta-1B (rbe)(EXTAVIA) 0.25 mg (8 million IU) powder for injection vial with diluent syringe [AUST R 160079], a therapeutic good that does not conform to certain labelling requirements outlined in Therapeutic Goods Order (TGO) 69. Specifically, the biological source of the active ingredient is not specified, and the relevant warning statements are not included on the syringe labels. Despite these non-compliances, the delegate has granted consent for this supply, subject to strict conditions. These conditions include limiting the consent to one batch of a maximum of 2000 units and requiring that the details of this batch be provided to the Therapeutic Goods Administration (TGA) upon shipment. Additionally, the outer carton must be the approved Australian specific carton, with only the inner labels being non-compliant. The obligations imposed by this consent on Novartis Pharmaceuticals Australia Pty Ltd are stringent. The company must ensure that the batch supplied is limited to the specified 2000 units and that it adheres to the requirement of using the approved Australian specific carton. Furthermore, the company must report the details of the batch to the TGA when the goods are shipped. These obligations are designed to ensure that the therapeutic goods supplied are still safe and of acceptable quality, despite the non-compliance with certain labelling requirements. Failure to comply with the conditions set out in the consent may result in serious legal and regulatory consequences. Under the Act, any breaches of the conditions could lead to enforcement actions by the TGA, including the potential imposition of fines or other penalties. Additionally, any adverse events or safety issues arising from the supply of non-compliant goods could result in further penalties or criminal charges against the company. The exact penalties for breaches are not detailed in the provided text, but they could range from financial penalties to criminal charges, depending on the severity and impact of the breach.